Clinical profile and outcome of D- haemolytic- uraemic syndrome in children from south India

HUS is characterised by a triad of micro-angiopathic haemolytic anaemia, thrombocytopenia and acute renal failure. HUS is usually characterised by oligoanuric renal failure similar to acute glomerulonephritis, but the outcome is guarded. Based on the presence or absence of a diarrhoeal prodrome, HUS may be classified as D+ or D-, respectively. D- HUS or atypical HUS (aHUS) accounts for <10% of all HUS cases encountered. It is a heterogenous and sometimes familial disorder with complement dysregulation being the most important aetiological factor. The prognosis is worse, with death rates of up to 25% in the acute phase, and 50% of cases requiring ongoing renal replacement therapy. [3]

[1]  Z. Prohászka,et al.  Diagnosis and classification of hemolytic uremic syndrome: the Hungarian experience. , 2011, Transplantation proceedings.

[2]  A. Garnier,et al.  Plasmatherapy in atypical hemolytic uremic syndrome. , 2010, Seminars in thrombosis and hemostasis.

[3]  P. Coppo,et al.  Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children , 2009, Pediatric Nephrology.

[4]  L. Zimmerhackl,et al.  Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS) , 2008, Pediatric Nephrology.

[5]  J. Atkinson,et al.  Complement regulatory genes and hemolytic uremic syndromes. , 2008, Annual review of medicine.

[6]  B. Boudailliez,et al.  Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. , 2007, Journal of the American Society of Nephrology : JASN.

[7]  P. Mannucci.  Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome: much progress and many remaining issues. , 2007, Haematologica.

[8]  J. Atkinson,et al.  Complement factor H and the hemolytic uremic syndrome , 2007, The Journal of experimental medicine.

[9]  G. Remuzzi,et al.  Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[10]  K. Moon,et al.  Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate , 2007, Pediatric Nephrology.

[11]  G. Remuzzi,et al.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. , 2006, Blood.

[12]  P. Zipfel,et al.  An interactive web database of factor H‐associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease‐associated mutations , 2006, Human mutation.

[13]  H. Repetto.  Long-term course and mechanisms of progression of renal disease in hemolytic uremic syndrome. , 2005, Kidney international. Supplement.

[14]  R. Oakes,et al.  Hemolytic uremic syndrome; pathogenesis, treatment, and outcome , 2005, Current opinion in pediatrics.

[15]  T. Hartung,et al.  Characterization of the Cytokine Immune Response in Children Who Have Experienced an Episode of Typical Hemolytic-Uremic Syndrome , 2003, Clinical Diagnostic Laboratory Immunology.

[16]  A. Garg,et al.  Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. , 2003, JAMA.

[17]  이지원.  Atypical hemolytic uremic syndrome in children , 2015 .

[18]  G. Remuzzi,et al.  Non-Shiga toxin-associated hemolytic uremic syndrome , 2006 .

[19]  D. Kavanagh,et al.  Atypical haemolytic uraemic syndrome. , 2006, British medical bulletin.

[20]  T. Gross,et al.  Hemolytic-uremic syndrome: a population-based study in Washington, DC and Baltimore, Maryland. , 1988, American journal of public health.